BERKELEY HEIGHTS, NJ - December 17, 2003
- Genta Incorporated (Nasdaq: GNTA) today announced the appointment
of Mr. Peter T. Tattle to the Company's Board of Directors. Mr.
Tattle retired after a long career at Johnson & Johnson as
Company Group Chairman for Pharmaceuticals in the Americas.
Mr. Tattle's 36- year tenure at Johnson & Johnson spanned
positions of increasing responsibility in sales, marketing and
product management, both domestically and internationally. He began
as a sales representative in 1965 for Ortho Pharmaceutical Canada
and advanced to Vice President of the Canadian pharmaceutical
business. In 1978, Mr. Tattle moved to New Jersey to lead Sales and
Product Management for Ortho Pharmaceutical Corporation as
Executive Director, eventually becoming Group Vice President of
that business. In 1984, he moved to England to assume the role of
Managing Director of Johnson & Johnson's pharmaceutical
business in the United Kingdom. In 1987, Mr. Tattle was appointed
International Vice President to lead the Cilag Pharmaceutical
companies worldwide, and in 1989 was named President of that
organization. From 1991 until his retirement in 2001, Mr. Tattle
served as Group Chairman of Johnson & Johnson's Pharmaceuticals
business in the Americas. Among other responsibilities, Mr. Tattle
currently serves on the boards of Xanthus Life Sciences Inc., DFB
Pharmaceuticals Inc., Catalina Marketing Corporation, and The
Cancer Institute of New Jersey. Mr. Tattle replaces Mr. Patrick
Zenner who has resigned from Genta's Board of Directors.
"The recent achievement of key clinical, regulatory, and
marketing milestones reinforces my enthusiasm to serve on Genta's
Board," remarked Mr. Tattle. "Genta has assembled an impressive
management team and Board of Directors, and I look forward to
working collaboratively in helping the Company meet its future
commercial objectives."
"We welcome Peter to Genta at this exciting time in our
organization," said Dr. Raymond P. Warrell, Jr., Genta's Chairman
and CEO. "We look to his expertise in marketing and product
management to enhance our commercial presence in the oncology
sector. On behalf of the Genta Board, I also want to express our
appreciation to Pat Zenner for his several years of valuable
service during a period of very rapid growth and expansion for our
Company."
About Genta Genta Incorporated is a biopharmaceutical company
with a diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company's lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite
TM
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
